Don A Bukstein1, Jacqueline Eghrari-Sabet2, Mary Hart3, Tanisha Hill4, Purvi Parikh5, Tonya A Winders3. 1. From the Allergy, Asthma and Sinus Center, Milwaukee, Wisconsin. 2. FAAR Institute, Washington, DC. 3. Allergy and Asthma Network, Vienna, Virginia. 4. Teva Pharmaceuticals, Parsippany, New Jersey; and. 5. Division of Infectious Disease and Immunology, Departments of Medicine and Pediatrics, New York University School of Medicine, New York University Langone Health, New York, New York.
Abstract
Background: Telehealth use increased during the coronavirus disease 2019 (COVID-19) pandemic to provide patient care while deferring to social distancing recommendations. Objective: Health-care provider and patient surveys were conducted to assess the impact of COVID-19 on the use and perception of telehealth visits for atopic and respiratory diseases. Methods: Health-care provider (N = 200) and patient (N = 200) surveys were conducted in the United States between September and October, 2020, and January, 2021. The participants were required to have used telehealth before or after March 1, 2020, the cutoff date selected to represent the start of the COVID-19 pandemic. Results: Before the pandemic, 40% of the health-care provider participants were conducting telehealth visits, which increased to 100% after the pandemic started. The average time spent per telehealth visit with patients increased from 13 to 16 minutes. A higher percentage of family medicine physicians/pediatricians had access to most monitoring tools than allergy/dermatology specialists both before the pandemic and after the pandemic started. Practice expenses reportedly increased after the pandemic started for 42% of participants. Before the pandemic, 27% of the patient participants used telehealth, which increased to 94% after the pandemic started. Ratings of "good" or "excellent" for the overall telehealth experience by the health-care provider participants improved from 44% before to 60% after the pandemic started, and by the patient participants improved from 77% to 88%. The willingness by the health-care provider participants to recommend telehealth to colleagues improved from 73% before to 83% after the pandemic started. The willingness by the patient participants to use telehealth again dropped slightly, from 94% to 89%. Conclusion: Telehealth visits for atopic and respiratory diseases increased during the COVID-19 pandemic. Telehealth experiences were overall positive, particularly for the patients.
Background: Telehealth use increased during the coronavirus disease 2019 (COVID-19) pandemic to provide patient care while deferring to social distancing recommendations. Objective: Health-care provider and patient surveys were conducted to assess the impact of COVID-19 on the use and perception of telehealth visits for atopic and respiratory diseases. Methods: Health-care provider (N = 200) and patient (N = 200) surveys were conducted in the United States between September and October, 2020, and January, 2021. The participants were required to have used telehealth before or after March 1, 2020, the cutoff date selected to represent the start of the COVID-19 pandemic. Results: Before the pandemic, 40% of the health-care provider participants were conducting telehealth visits, which increased to 100% after the pandemic started. The average time spent per telehealth visit with patients increased from 13 to 16 minutes. A higher percentage of family medicine physicians/pediatricians had access to most monitoring tools than allergy/dermatology specialists both before the pandemic and after the pandemic started. Practice expenses reportedly increased after the pandemic started for 42% of participants. Before the pandemic, 27% of the patient participants used telehealth, which increased to 94% after the pandemic started. Ratings of "good" or "excellent" for the overall telehealth experience by the health-care provider participants improved from 44% before to 60% after the pandemic started, and by the patient participants improved from 77% to 88%. The willingness by the health-care provider participants to recommend telehealth to colleagues improved from 73% before to 83% after the pandemic started. The willingness by the patient participants to use telehealth again dropped slightly, from 94% to 89%. Conclusion: Telehealth visits for atopic and respiratory diseases increased during the COVID-19 pandemic. Telehealth experiences were overall positive, particularly for the patients.
Authors: Tonya Winders; Lawrence DuBuske; Don A Bukstein; Eli O Meltzer; Dana Wallace; Karen Rance Journal: Allergy Asthma Proc Date: 2021-05-24 Impact factor: 2.587
Authors: I Fernández-de-Alba; C Brigido; I García-Gutierrez; D Antolín-Amérigo; S Sánchez-García Journal: J Investig Allergol Clin Immunol Date: 2020-07-02 Impact factor: 4.333
Authors: Amanda Moreland; Christine Herlihy; Michael A Tynan; Gregory Sunshine; Russell F McCord; Charity Hilton; Jason Poovey; Angela K Werner; Christopher D Jones; Erika B Fulmer; Adi V Gundlapalli; Heather Strosnider; Aaron Potvien; Macarena C García; Sally Honeycutt; Grant Baldwin Journal: MMWR Morb Mortal Wkly Rep Date: 2020-09-04 Impact factor: 17.586
Authors: Elissa M Abrams; Marcus Shaker; John Oppenheimer; Ray S Davis; Don A Bukstein; Matthew Greenhawt Journal: J Allergy Clin Immunol Pract Date: 2020-07-14
Authors: Lisa M Koonin; Brooke Hoots; Clarisse A Tsang; Zanie Leroy; Kevin Farris; Tilman Jolly; Peter Antall; Bridget McCabe; Cynthia B R Zelis; Ian Tong; Aaron M Harris Journal: MMWR Morb Mortal Wkly Rep Date: 2020-10-30 Impact factor: 17.586